Abeona Therapeutics® Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
Provided By GlobeNewswire
Last update: Nov 14, 2024
FDA accepts BLA resubmission of pz-cel in recessive dystrophic epidermolysis bullosa and sets PDUFA target action date of April 29, 2025
Company makes significant progress toward potential commercialization of pz-cel in 2025; Builds momentum with payor discussions and target treatment centers
Read more at globenewswire.comNASDAQ:ABEO (2/21/2025, 8:00:00 PM)
5.78
-0.04 (-0.69%)
Find more stocks in the Stock Screener
